
Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices

Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Office of Medical Policy, 301-796-3093; (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010; or (CDRH) Office of Clinical Evidence and Analysis, CDRHClinicalEvidence@fda.hhs.gov.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)**

**September 2021
Drug Safety**

Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices

Guidance for Industry

Additional copies are available from:

*Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov*

<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>

and/or

*Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov*

<https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>

and/or

*Office of Policy
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 66, Room 5431
Silver Spring, MD 20993-0002
Email: CDRH-Guidance@fda.hhs.gov*

<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)**

**September 2021
Drug Safety**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	2
III.	DEFINITIONS	4
	A. DRUGS	4
	1. <i>Adverse Event (21 CFR 312.32(a))</i>	4
	2. <i>Adverse Reaction and Suspected Adverse Reaction (21 CFR 312.32(a))</i>	4
	3. <i>Serious (21 CFR 312.32(a))</i>	5
	B. DEVICES	6
	1. <i>Unanticipated Adverse Device Effect (21 CFR 812.3(s))</i>	6
	2. <i>Serious</i>	6
IV.	INVESTIGATOR REPORTING TO SPONSORS FOR IND STUDIES	7
	A. Assessment of Causality	8
	B. Study Endpoints	8
	C. Nonserious Adverse Events	9
V.	INVESTIGATOR REPORTING TO INSTITUTIONAL REVIEW BOARDS FOR IND STUDIES	9
	A. Adverse Events as Unanticipated Problems That Must Be Reported to the IRB	9
	B. Other Unanticipated Problems Requiring Reporting to the IRB	10
VI.	INVESTIGATOR REPORTING TO SPONSORS AND INSTITUTIONAL REVIEW BOARDS FOR IDE STUDIES	11

Contains Nonbinding Recommendations

Draft — Not for Implementation

1
2
3
4
**Investigator Responsibilities —
Safety Reporting for Investigational Drugs and Devices
Guidance for Industry¹**

5
6
7
8
9
10
11
This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

12
13
14 **I. INTRODUCTION**

15
16 This guidance is intended to help clinical investigators comply with the following safety
17 reporting requirements:

- 18
19
 - Investigational new drug application (IND) studies² under § 312.64(b) (21 CFR 312.64(b))
 - Investigational device exemption (IDE) studies under § 812.150 (21 CFR 812.150)

20
21
22
23
24 Recommendations are provided to help investigators identify the following:

- 25
26
 1. For drugs — Identify safety information that is considered an unanticipated problem involving risk to human subjects or others and that therefore requires prompt reporting to institutional review boards (IRBs) under § 312.66 (21 CFR 312.66)
 2. For devices — Identify safety information that meets the requirements for reporting unanticipated adverse device effects (UADEs) to sponsors and IRBs under § 812.150(a)(1) (21 CFR 812.150(a)(1))

27
28
29
30
31
32
33
34 This document incorporates concepts pertaining to investigator responsibilities for adverse event
35 reporting described in the guidance for industry and investigators *Safety Reporting Requirements*
36 *for INDs and BA/BE Studies* (December 2012) (the 2012 final guidance) and in the guidance for

¹ This guidance has been prepared by the Office of Medical Policy in the Center for Drug Evaluation and Research in cooperation with the Center for Biologics Evaluation and Research and the Center for Devices and Radiological Health at the Food and Drug Administration.

² This guidance also provides relevant information for companies reporting serious adverse events (SAEs) for IND-exempt bioavailability (BA)/bioequivalence (BE) studies under § 320.31(d)(3) (21 CFR 320.31(d)(3)).

Contains Nonbinding Recommendations

Draft — Not for Implementation

37 clinical investigators, sponsors, and IRBs *Adverse Event Reporting to IRBs—Improving Human*
38 *Subject Protection* (January 2009) (the 2009 procedural final guidance).³

39
40 When finalized, this guidance will supersede corresponding sections in the 2012 final guidance
41 and the 2009 procedural final guidance. Until that time, however, the 2012 final guidance and
42 the 2009 procedural final guidance continue to represent FDA’s current thinking on investigator
43 responsibilities for safety reporting for investigational medical products.⁴

44
45 The contents of this document do not have the force and effect of law and are not meant to bind
46 the public in any way, unless specifically incorporated into a contract. This document is
47 intended only to provide clarity to the public regarding existing requirements under the law.
48 FDA’s guidance documents, including this guidance, should be viewed only as
49 recommendations, unless specific regulatory or statutory requirements are cited. The use of the
50 word *should* in Agency guidances means that something is suggested or recommended, but not
51 required.

52
53

II. BACKGROUND

54
55

56 In the *Federal Register* of September 29, 2010 (75 FR 59935), FDA published a final rule
57 (referred to in this guidance as the 2010 IND safety reporting rule) amending the IND safety
58 reporting requirements under § 312.32 and adding safety reporting requirements for persons
59 conducting bioavailability (BA) and bioequivalence (BE) studies under § 320.31 (21 CFR
60 320.31). Subsequently, the 2012 final guidance was published to help sponsors and investigators
61 comply with safety reporting requirements for INDs and for IND-exempt BA/BE studies.

62

63 Recently, the recommendations for investigators provided in the 2012 final guidance were
64 updated, merged, and published for notice and comment purposes in the draft guidance for
65 industry *Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for*
66 *IND and Bioavailability/Bioequivalence Studies* (June 2021) (the merged 2021 draft guidance).⁵
67 The merged 2021 draft guidance does not, however, include the recommendations for
68 investigator responsibilities that are included in the 2012 final guidance, and such
69 recommendations on investigator responsibilities are the primary focus of this guidance.

70

³ We update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

⁴ For combination products as defined in 21 CFR 3.2(e), safety reporting under the IDE or IND should include a complete discussion of the event with respect to the combination product as a whole, including each constituent part of the product, as appropriate, based on the available information. If you have questions related to safety reporting for your investigational product, please contact the lead review division for the IND or IDE. You may also contact the Office of Combination Products at combination@fda.gov for further assistance as needed.

⁵ When final, this guidance will represent FDA’s current thinking on this topic.

Contains Nonbinding Recommendations

Draft — Not for Implementation

71 The IND safety reporting requirements in § 312.32 apply to sponsors,⁶ not investigators.
72 However, investigators may find it helpful to understand overall sponsor responsibilities
73 regarding IND safety reporting requirements. The regulations in § 312.32(c)(1) require the
74 sponsor to notify FDA⁷ and all participating investigators (i.e., all investigators to whom the
75 sponsor is providing the drug under the sponsor’s INDs or under any sponsor-investigator’s
76 IND) in an IND safety report of potential serious risks identified from clinical trials⁸ or any other
77 source, as soon as possible, but in no case later than 15 calendar days after the sponsor
78 determines that the information qualifies for reporting under § 312.32(c)(1)(i) through (iv),
79 which includes any of the following:

- 80
- 81 • Serious and unexpected suspected adverse reactions⁹
- 82
- 83 • Findings from epidemiological studies, pooled analyses of multiple studies, or clinical
- 84 studies that suggest a significant risk in humans exposed to the drug
- 85
- 86 • Findings from animal or in vitro testing that suggest a significant risk in humans exposed
- 87 to the drug
- 88
- 89 • Any clinically important increase in the rate of a serious suspected adverse reaction over
- 90 that listed in the protocol or investigator brochure
- 91

92 For IND-exempt BA/BE studies, § 320.31(d)(3) states that “[t]he person conducting the study,
93 including any contract research organization, must notify FDA and all participating investigators
94 of any serious adverse event, as defined in § 312.32(a), observed during the conduct of the study
95 as soon as possible but in no case later than 15 calendar days after becoming aware of its
96 occurrence.”

97

98 Section 320.31(d)(3) also requires the person conducting the study (including any contract
99 research organization) to notify FDA of any “fatal or life-threatening adverse event from the
100 study as soon as possible but in no case later than 7 calendar days after becoming aware of its
101 occurrence.” However, the regulation does not require all investigators to be notified of such
102 events within that time frame.

103

104 For device studies under an IDE, the regulations in § 812.150(a)(1) require investigators to
105 submit to the sponsor and to the reviewing IRB a report of any UADE occurring during an
106 investigation as soon as possible, but no later than 10 working days after the investigator first

⁶ Requirements under § 312.32 also apply to sponsor-investigators, as defined in § 312.3.

⁷ A sponsor-investigator who receives an IND safety report for another study for which they are not the sponsor does not need to submit that IND safety report to FDA if it has already been submitted. See the draft guidance for industry *Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies*.

⁸ For the purposes of this guidance, FDA uses the terms *clinical trial* and *clinical investigation* interchangeably.

⁹ Note that if the suspected adverse reaction is fatal or life-threatening, the requirement is to report as soon as possible but no later than 7 calendar days after the sponsor’s initial receipt of the information (see § 312.32(c)(2)).

Contains Nonbinding Recommendations

Draft — Not for Implementation

107 learns of the effect. In addition, the regulations in 21 CFR 812.46(b) and 812.150(b)(1) require
108 sponsors to conduct an evaluation of any UADE and to report the results to FDA, all reviewing
109 IRBs, and all participating investigators within 10 working days after the sponsor first receives
110 notice of the effect.

111

112

113 III. DEFINITIONS

114

115 A. DRUGS

116

117 The 2010 IND safety reporting rule defined a number of terms related to safety reporting.
118 Although the terms defined in § 312.32 refer to sponsor reporting responsibilities, FDA is using
119 these terms consistently for the purposes of the investigator reporting requirements for drugs¹⁰
120 discussed in this guidance. These definitions, accompanied by further explanation and examples,
121 can also be found in the merged 2021 draft guidance. For ease of reference, the following
122 definitions from § 312.32(a) are included in this guidance as well, along with additional thinking
123 about the meaning of these terms.

124

125 1. *Adverse Event (21 CFR 312.32(a))*

126

127 Adverse event (AE) means “any untoward medical occurrence associated with the use of a drug
128 in humans, whether or not considered drug related” (§ 312.32(a)).

129

130 FDA considers an *adverse event* (also referred to as an *adverse experience*) to include any
131 unfavorable sign (e.g., an abnormal laboratory finding), symptom, or clinical outcome
132 temporally associated with the use of a test drug, active control, or placebo, regardless of
133 whether the event is thought to be related to the drug. An adverse event can arise during any use
134 of a drug or biologic (e.g., use for a purpose other than FDA-approved indication or in
135 combination with another drug) and with any route of administration, formulation, or dose,
136 including an overdose.

137

138 2. *Adverse Reaction¹¹ and Suspected Adverse Reaction (21 CFR 312.32(a))*

139

140 An *adverse reaction* means any adverse event *caused* by a drug. *Suspected adverse reaction*
141 means “any adverse event for which there is a *reasonable possibility* that the drug caused the
142 adverse event. For the purposes of IND safety reporting, *reasonable possibility* means there is
143 evidence to suggest a causal relationship between the drug and the adverse event. Suspected

¹⁰ For the purposes of this guidance, *drug* or *drug product* is used to refer to human drugs and human biological products that are regulated as drugs.

¹¹ For the purposes of prescription drug labeling, the term *adverse reaction* is defined to mean “an undesirable effect, reasonably associated with use of a drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence. This definition does not include all adverse events observed during use of a drug, only those adverse events for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event” (21 CFR 201.57(c)(7); see also 21 CFR 201.80(g)).

Contains Nonbinding Recommendations

Draft — Not for Implementation

144 adverse reaction implies a lesser degree of certainty about causality than adverse reaction”
145 (emphasis added) (§ 312.32(a)).

146
147 Both an adverse reaction and a suspected adverse reaction require evidence of a causal
148 relationship between the drug and the adverse event (§ 312.32(a)). Therefore, if no drug has
149 been administered, an adverse event is not reportable under IND safety reporting regulations.^{12,13}

150
151 The following examples provided in the safety reporting regulation (§ 312.32(c)(1)(i)) illustrate
152 the meaning of *reasonable possibility* with respect to a determination that there may be a causal
153 relationship between the drug and the adverse event:

- 154
155 • A single occurrence of an event that is uncommon and known to be strongly associated
156 with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome).
- 157
158 • One or more occurrences of an event that is not commonly associated with drug exposure
159 but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture).
- 160
161 • An aggregate analysis of specific events observed in a clinical trial, indicating that they
162 occur more frequently in the drug treatment group than in a concurrent or historical
163 control group. Such events may be known consequences of the underlying disease or
164 condition or events that commonly occur in the study population independent of drug
165 therapy. Such events could also be related to an intervention or therapy that is standard
166 of care for the disease (e.g., background treatment).

167
168 To determine whether an adverse event should be classified as a *suspected adverse reaction* or
169 an adverse reaction, the sponsor must evaluate the available evidence (§ 312.32(b)) and make a
170 judgment about the likelihood that the drug caused the adverse event.

171
172 3. *Serious (21 CFR 312.32(a))*

173
174 An adverse event, adverse reaction, or suspected adverse reaction is considered *serious*

175
176 if, in the view of either the investigator or the sponsor, it results in any of the
177 following: death, a life-threatening adverse event, inpatient hospitalization or
178 prolongation of existing hospitalization, a persistent or significant incapacity or
179 substantial disruption of the ability to conduct normal life functions, or a
180 congenital anomaly/birth defect. Important medical events that might not result in
181 death, are not life-threatening, and do not require hospitalization may be
182 considered serious when, based upon appropriate medical judgment, they may
183 jeopardize the patient or subject and may require medical or surgical intervention

¹² However, for clinical investigations that involve an invasive procedure that would not occur other than due to participation in the trial (e.g., intrahepatic artery administration or a kidney biopsy), FDA may request that sponsors also report SAEs associated with such a procedure, even if the investigational product is not administered.

¹³ Investigator reporting requirements under §§ 312.64(b) and 312.66 may still apply even where no drug has been administered.

Contains Nonbinding Recommendations

Draft — Not for Implementation

184 to prevent one of the outcomes listed in this definition. Examples of such medical
185 events include allergic bronchospasm requiring intensive treatment in an
186 emergency room or at home, blood dyscrasias or convulsions that do not result in
187 inpatient hospitalization, and the development of drug dependency or abuse.
188 (§ 312.32(a))
189

190 The sponsor and the investigator must evaluate whether an event meets the definition of *serious*.
191 See §§ 312.32(c)(1)(i) and 312.64(b). Because identifying serious adverse events (SAEs) is
192 critically important for the evaluation of potential significant safety problems, FDA considers it
193 important to take into account both the investigator's and the sponsor's assessments. Therefore,
194 if the sponsor or investigator believes that the event is serious, the event must be considered
195 serious and must be evaluated by the sponsor for expedited reporting (§§ 312.32(a) and
196 312.32(c)(1)).
197

B. DEVICES

1. Unanticipated Adverse Device Effect (21 CFR 812.3(s))

200
201
202 *An unanticipated adverse device effect (UADE)*
203

204 means any serious adverse effect on health or safety or any life-threatening
205 problem or death caused by, or associated with, a device, if that effect, problem,
206 or death was not previously identified in nature, severity, or degree of incidence
207 in the investigational plan or application (including a supplementary plan or
208 application), or any other unanticipated serious problem associated with a device
209 that relates to the rights, safety, or welfare of subjects. (§ 812.3(s))
210

2. Serious

211
212
213 What qualifies as a serious adverse effect, as that term is used in the definition of UADE, would
214 be specific to the device and the study in which it is being used or tested. Generally, a serious
215 adverse effect is one that is determined by the investigator or sponsor to be life-threatening,
216 require hospitalization, result in disability or permanent damage, result in a congenital anomaly
217 or birth defect, or require an intervention to prevent permanent impairment or damage. In the
218 protocol, the sponsor should include information on adverse effects that helps investigators
219 determine what would qualify as a serious adverse effect. Examples of adverse effects that could
220 be considered serious include organ perforation and thrombus formation inside an aortic
221 endovascular graft.
222

Contains Nonbinding Recommendations

Draft — Not for Implementation

223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252

IV. INVESTIGATOR REPORTING TO SPONSORS FOR IND STUDIES¹⁴

Most of the information about the safety of a drug prior to marketing comes from clinical trials. Adverse event reports from investigators are therefore critically important, given that it is the investigators who observe subjects' responses to an investigational drug. The investigator must immediately report to the sponsor any SAEs,¹⁵ regardless of whether the investigator believes the SAEs are related to the drug (§ 312.64(b)). This requirement includes those SAEs (1) listed in the safety surveillance plan as anticipated to occur in the study population independent of drug exposure or (2) listed in the investigator brochure as predicted to occur with the drug.¹⁶ The one exception to this requirement (discussed in section IV.B of this guidance) involves study endpoints that are also SAEs (e.g., myocardial infarction, stroke, or death in trials evaluating drugs intended to treat cardiovascular conditions), which “must be reported in accordance with the protocol unless there is evidence suggesting a causal relationship between the drug and the event. . . . In that case, the investigator must immediately report the event to the sponsor.” (§ 312.64(b)). Non-serious AEs must be reported according to the timetable for reporting specified in the protocol (§ 312.64(b)).

For the purposes of this guidance, the Agency interprets *immediately* to be as soon as feasible after the investigator recognizes an event is an SAE and obtains relevant information for the sponsor. Such information would generally include a specified subject, a suspected drug (if any), the reporting source (if not the investigator themselves), and a clinical description of the event, including an assessment of whether a reasonable possibility exists that the drug caused the event. Although more data may be collected and submitted later, the initial report must be submitted as soon as possible (§ 312.64(b)). FDA recommends that this time frame for submitting such initial information also be specified in the protocol and anticipates that it will generally be no longer than 1 calendar day. Investigators are not required to determine whether an event is *unexpected* (as defined in § 312.32(a));¹⁷ this determination is a sponsor's responsibility (see § 312.32(c)(1)(i)).

¹⁴ Guidance provided in this section may be applicable for companies conducting IND-exempt BA/BE studies to comply with § 320.31(d)(3).

¹⁵ Study endpoints that are SAEs must be reported in accordance with the protocol unless there is evidence suggesting a causal relationship between the drug and the event (§ 312.64(b)).

¹⁶ For further information about anticipated and expected adverse events, see the draft guidance for industry *Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies*.

¹⁷ “An adverse event or suspected adverse reaction is considered ‘unexpected’ if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. . . . ‘Unexpected,’ as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation” (§ 312.32(a)).

Contains Nonbinding Recommendations

Draft — Not for Implementation

253 **A. Assessment of Causality**

254
255 FDA believes that the sponsor is generally better positioned than the individual investigator to
256 determine whether an SAE should be classified as a *suspected* adverse reaction. This is
257 especially true for events that may warrant analysis of more than a single event to determine if
258 any are possibly related to the drug, because the sponsor may have access to SAE reports from
259 multiple study sites and multiple studies and would be able to aggregate and analyze these
260 reports. Moreover, the sponsor is likely to be more familiar with the drug's mechanism of
261 action, class effects, and other information. To determine whether an SAE meets the definition
262 of a suspected adverse reaction, the sponsor must evaluate the available evidence (as separately
263 required by § 312.32(b)) and make a judgment about the likelihood that the drug actually caused
264 the adverse event. For these reasons, except for most study endpoints, investigators must
265 immediately report any SAE to the sponsor (as mentioned previously), whether or not the
266 investigator considers the event to be drug related (§ 312.64(b)).

267
268 Although the sponsor is ultimately responsible for determining whether an SAE should be
269 classified as a *suspected* adverse reaction, the investigator's view is important for the sponsor to
270 carefully consider when assessing the safety of the drug and determining whether to report an
271 event expeditiously to FDA. The investigator, who monitors the subject's response to the drug,
272 is knowledgeable about the subject's clinical state (e.g., medical history, concomitant
273 medications, symptoms, pertinent test results, timing of events relative to drug exposure).
274 Therefore, the investigator may be sensitive to distinctions between events that may be related to
275 study drug exposure versus those caused by the underlying disease process and/or concomitant
276 therapies.

277
278 For these reasons, the investigator must include in the report to the sponsor an assessment of
279 whether there is a reasonable possibility that the drug caused the event (§ 312.64(b)). For the
280 purposes of § 312.64(b), FDA interprets *reasonable possibility* to mean there is evidence to
281 suggest a causal relationship between the drug and the adverse event. This interpretation is
282 consistent with the definition of *suspected adverse reaction* in § 312.32(a). Factors that should
283 be considered when making a causality assessment include, but are not limited to, temporal
284 relationship of the event to drug administration; biologic plausibility, based on the mechanism of
285 action of the drug or similar drugs in the same class; nonclinical evidence; and dechallenge-
286 rechallenge information.

287 288 **B. Study Endpoints**

289
290 In studies where trial endpoints meet the criteria for SAEs (such as myocardial infarction or
291 death), the investigator must report these as endpoints, in accordance with the protocol, and not
292 as SAEs to the sponsor (§ 312.64(b)). An exception to this requirement, however, is when there
293 is evidence suggesting a causal relationship between a drug and an event (e.g., death from
294 anaphylaxis after exposure). Even if such an event is a component of the endpoint (e.g., all-
295 cause mortality), SAEs meeting this criterion must be immediately reported to the sponsor
296 (§ 312.64(b)).

297

Contains Nonbinding Recommendations

Draft — Not for Implementation

298 **C. Nonserious Adverse Events**

299
300 The investigator must record nonserious adverse events and report them to the sponsor according
301 to the timetable specified in the protocol (§ 312.64(b)). Often, nonserious events are recorded
302 and are submitted to the sponsor and reviewed at regular intervals throughout the course of the
303 investigation.

304 305 306 **V. INVESTIGATOR REPORTING TO INSTITUTIONAL REVIEW BOARDS FOR** 307 **IND STUDIES¹⁸**

308
309 Investigators are required to “promptly report to the IRB . . . all unanticipated problems
310 involving risk to human subjects or others” (§ 312.66), including adverse events that represent
311 unanticipated problems, as further described in this section.¹⁹ Note that the requirements for
312 IND safety reporting under § 312.32 do not address safety reporting by investigators to IRBs.
313 The types of unanticipated problems that must be reported to the IRB are discussed in sections A
314 and B below.

315 **A. Adverse Events as Unanticipated Problems That Must Be Reported to the** 316 **IRB**

317
318
319 Investigators are required under § 312.66 to report all “unanticipated problems involving risk to
320 human subjects or others” to the IRB. FDA considers a serious and unexpected adverse event
321 that meets the criteria for sponsor reporting to FDA and all investigators in an IND safety report
322 under § 312.32 to be an unanticipated problem involving risk to human subjects or others that
323 therefore must be reported to the IRB by the investigator.²⁰

324
325 IND safety reports and reports of SAEs from IND-exempt BA/BE studies²¹ provide FDA and
326 participating investigators with important information relevant to the safety of human subjects
327 receiving the investigational drug. IND safety reports provide information on potential serious
328 risks, including unexpected SAEs for which there is a reasonable possibility that the

¹⁸ Guidance provided in this section may be applicable for companies conducting IND-exempt BA/BE studies to comply with § 320.31(d)(3).

¹⁹ We note that IND-exempt BA/BE studies are not subject to the requirements in § 312.66. However, they must still be conducted in compliance with the requirements for review by IRBs established in 21 CFR part 56. See § 320.31(d)(2). Section 56.108(b)(1) provides that an IRB will ensure the prompt reporting to the IRB of “any unanticipated problems involving risks to human subjects or others. . . .” FDA interprets this language in a manner consistent with the interpretation of § 312.66 laid out in this guidance.

²⁰ In general, the occurrence of an SAE is very unusual in a BA/BE study because the number of subjects enrolled is small, the subjects are usually healthy volunteers, and drug exposure is typically brief, but often at the highest available dosage. For these reasons, FDA considers the occurrence of any SAE in a BA/BE study that is subject to an IND to be an unanticipated problem involving risk to human subjects. Accordingly, the investigator of a BA/BE study that is subject to an IND must report to the IRB any SAE that occurs in the study (21 CFR 312.66).

²¹ See § 320.31(d)(3).

Contains Nonbinding Recommendations

Draft — Not for Implementation

329 investigational drug caused the event. Reports of SAEs from IND-exempt BA/BE studies
330 provide information on SAEs that occur in those studies, all of which are important to consider
331 for human subject protection reasons because the occurrence of SAEs in BA/BE studies is
332 unusual: the number of subjects enrolled is small, the subjects are usually healthy volunteers,
333 and drug exposure is typically brief, but often at the highest available dosage.
334

335 Reviewing IND safety reports and reports of SAEs from IND-exempt BA/BE studies is essential
336 for protecting the safety of human subjects because each report represents important safety
337 information regarding the investigational drug. FDA considers the review of these reports
338 critical to fulfilling the investigator's responsibility under § 312.60 (21 CFR 312.60) to protect
339 the safety of subjects under their care. For these reasons, investigators must review all IND
340 safety reports and reports of safety information from IND-exempt BA/BE studies received (see
341 § 312.60). In addition, investigators must submit these reports to the IRB because the reports
342 describe important safety information representing unanticipated problems involving risks to
343 human subjects or others (§ 312.66). Many study protocols specify that the sponsor will submit
344 IND safety reports to the IRB on the investigator's behalf. In these situations, where the
345 investigator receives confirmation that the report has been sent to the IRB (e.g., the investigator
346 is copied on the report sent to the IRB by the sponsor), FDA would not expect an investigator to
347 provide the IRB with a duplicate copy of the report.²²
348

B. Other Unanticipated Problems Requiring Reporting to the IRB

350
351 Some events not meeting the criteria for reporting in an IND safety report or as a BA/BE study
352 premarket SAE would still be considered unanticipated problems involving risk to human
353 subjects or others and, under § 312.66, would require reporting to the IRB by the investigator.
354 Such events may occur at the subject, site, and/or study level. Some possible examples may
355 include reports of medication errors (such as receipt of wrong dose or contaminated study
356 medication), breach of privacy/confidentiality (such as disclosure of personally identifiable
357 information), untimely destruction of study records, and other scenarios. The investigator must
358 report any unanticipated problems involving risk to human subjects or others. This requirement
359 applies regardless of whether the unanticipated problem is related to the study drug or related to
360 study procedures. Such unanticipated problems may include serious unexpected adverse events
361 that occur prior to test article administration or during a washout period or that are attributable to
362 a screening procedure (e.g., renal failure after receipt of an imaging contrast agent).
363

364 Finally, the IRB's written procedures or institutional policy may require the investigator to
365 submit to the IRB other unanticipated problems in addition to those that qualify for reporting
366 under § 312.66. The investigator should be familiar with and adhere to the IRB's written
367 procedures for reporting unanticipated problems involving risks to human subjects or others to
368 the IRB (see 21 CFR 56.108(b)(1)). Also, as part of their clinical trial monitoring responsibility,
369 we understand that sponsors generally require that investigators report such unanticipated
370 problems to the sponsors as well.
371
372

²² Note that such an agreement should be documented.

Contains Nonbinding Recommendations

Draft — Not for Implementation

373 **VI. INVESTIGATOR REPORTING TO SPONSORS AND INSTITUTIONAL**
374 **REVIEW BOARDS FOR IDE STUDIES**

375
376 The IDE regulations require investigators to report UADEs to both sponsors and IRBs. Similar
377 to the handling of SAEs described previously for IND studies, FDA believes that the sponsor is
378 generally better positioned than the individual investigator to assess UADEs, given that the
379 sponsor has access to UADE reports from multiple study sites and multiple studies and is able to
380 aggregate and analyze these reports. Therefore, UADE reports are critical to the process, and the
381 IDE regulations require not only timely reporting for investigators, but also timely evaluation by
382 sponsors, described as follows:

- 383
- 384 • For device studies, investigators are required to submit a report of a UADE to the sponsor
385 and the reviewing IRB as soon as possible, but in no event later than 10 working days
386 after the investigator first learns of the effect (§ 812.150(a)(1)).
 - 387
 - 388 • Sponsors must immediately conduct an evaluation of a UADE and must report the results
389 of the evaluation to FDA, all reviewing IRBs, and all participating investigators within
390 10 working days after the sponsor first receives notice of the effect (§§ 812.46(b) and
391 812.150(b)(1)).
- 392

393 What qualifies as a UADE is expected to vary depending on the specific device and the way the
394 device is used within the study. Therefore, sponsors are required to include risk information in
395 the investigational plan, which may help investigators identify and assess potential UADEs
396 (§§ 812.25(c) and 812.45).

397
398 In addition to reporting UADEs, according to § 812.150(a)(3), investigators are to provide
399 progress reports to sponsors, monitors, and IRBs²³ at regular intervals, and no less than yearly.
400 Such reports should provide information to sponsors about both anticipated and unanticipated
401 adverse device effects.

²³ The terms *sponsor*, *monitor*, and *IRB* in the context of device studies are defined in § 812.3.